The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The European Commission expanded approval of the CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (liso-cel; Breyanzi®) in patients with relapsed or refractory
In this video interview with SOHO Insider Al-Ola A. Abdallah, MD, associate professor and director of the Plasma Cell Disorder program at the
The US Food and Drug Administration (FDA) approved epcoritamab (EPKINLY) in combination with rituximab, lenalidomide, and lenalidomide (RLL) for adult patients with relapsed
The inaugural SOHO-EGYPT Meeting (November 5 to 6) was a joint session within NCI's BGO 2025 Congress ("Bridging Gaps in Oncology," November 5
As a resident physician who is fascinated by hematologic malignancies, Maha Hameed, MD, brings a distinctive combination of scientific intrigue and personal drive
SOHO KSA held its first regional meeting in Riyadh, the Kingdom of Saudi Arabia (KSA). The two-day event was held at the Intercontinental
The US Food and Drug Administration has approved daratumumab co-formulated with hyaluronidase (DARZALEX FASPRO®), as a single-agent therapy for adults with high-risk smoldering multiple
The US Food and Drug Administration (FDA) granted interchangeable biosimilar designation to denosumab-bnht (Bomyntra) for patients with multiple myeloma (MM) to prevent skeletal-related
At the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), a new pilot program debuted to educate and empower the
Elias Jabbour, MD, leukemia professor at the University of Texas MD Anderson Cancer Center, moderates a discussion on acute lymphoblastic leukemia (ALL) MRD-guided
